CN108523126B - Composition for improving blood sugar level and preparation method thereof - Google Patents
Composition for improving blood sugar level and preparation method thereof Download PDFInfo
- Publication number
- CN108523126B CN108523126B CN201810373933.3A CN201810373933A CN108523126B CN 108523126 B CN108523126 B CN 108523126B CN 201810373933 A CN201810373933 A CN 201810373933A CN 108523126 B CN108523126 B CN 108523126B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- chestnut
- extract
- shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001070941 Castanea Species 0.000 claims abstract description 82
- 235000014036 Castanea Nutrition 0.000 claims abstract description 82
- 239000000284 extract Substances 0.000 claims abstract description 81
- 239000000843 powder Substances 0.000 claims abstract description 62
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 12
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 12
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 12
- 240000000249 Morus alba Species 0.000 claims abstract description 11
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 11
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 9
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 8
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 8
- 239000011651 chromium Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 7
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 6
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 6
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 6
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 6
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 6
- 235000019895 oat fiber Nutrition 0.000 claims abstract description 6
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims abstract description 6
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 210000003038 endothelium Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000000643 oven drying Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241001633680 Polygonatum odoratum Species 0.000 claims 1
- 241000756042 Polygonatum Species 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004139 alpha-Amylases Human genes 0.000 description 5
- 108090000637 alpha-Amylases Proteins 0.000 description 5
- 229940024171 alpha-amylase Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition for improving blood sugar level and a preparation method thereof, wherein the composition comprises the following raw materials: 25-40 parts of chestnut peel extract, 10-20 parts of mulberry leaf extract, 3-5 parts of oat beta-glucan, and also can be further added with 5-10 parts of bitter gourd powder, 1-2 parts of chromium-containing yeast powder, 5-10 parts of bitter gourd extract, 10-20 parts of barley malt, 5-10 parts of haematococcus pluvialis powder, 3-5 parts of oat fiber, 5-10 parts of yam powder, 1-2 parts of chrysanthemum powder, 3-5 parts of buckwheat powder, 4-7 parts of polygonatum powder, 3-5 parts of radix puerariae powder and 20.1-1 parts of vitamin B.
Description
Technical Field
The invention relates to the technical field of health food and processing treatment thereof, in particular to a nutritional composition capable of improving blood sugar level and a preparation method thereof.
Background
With the improvement of life quality, the dietary structure is continuously changed, more and more high-sugar and high-fat foods are ingested, the incidence rate of diabetes is rapidly increased, the diabetes is second to cardiovascular diseases and tumors at present, the third most common disease is diabetes, the diabetes is a chronic disease, the prevalence rate of diabetes of Chinese adults is as high as nearly 10%, and the control and prevention of diabetes are very difficult. The prevention or improvement of blood sugar level is important for the treatment of diabetes, and when medication is used, daily diet is also important, and improper diet control can cause fluctuation of blood sugar and even aggravate the risk of hyperglycemia.
At present, more researches focus on traditional Chinese medicines or health care products with homology of medicine and food to control the blood sugar level. For example, chinese patent CN2014102044678 discloses a nutritional meal replacement powder suitable for people with hyperglycemia, which comprises dietary fiber powder, fruit and vegetable powder, mulberry leaf extract, maltodextrin, stevioside, hydrolyzed whey protein, multivitamins and complex minerals, has a certain auxiliary blood sugar lowering effect on diabetes patients, has good taste, and can be taken as meal replacement food. Chinese patent CN2008100066094 discloses a special diet containing short peptides for diabetic patients, which takes food-borne short peptides as main raw materials, adds extracts of Chinese yam, mulberry leaf, kudzuvine root, Siberian solomonseal rhizome, corn silk, tuckahoe, dark plum fruit, fragrant solomonseal rhizome and other medicinal and edible Chinese herbal medicines, and then is supplemented with oligopeptide, vitamin and mineral matter to form a compound formula, and can assist and control the blood sugar level of the diabetic patients, improve the immunity of the organism and prevent diabetic complications through the combined action of the food-borne short peptides, bioactive components in the medicinal and edible Chinese herbal medicine extracts, the oligopeptide and other various silvers.
It can be seen that, because the etiology and mechanism of diabetes are complex, the research at present is mainly focused on adopting composite compositions, and the full play of the cooperativity of the formula through the mutual compatibility of multiple components is a research hotspot at present.
The extract of the chestnut shell has been studied to control the blood sugar level, and Japanese patent laid-open No. 2006-1872 discloses the use of the extract of the chestnut shell for controlling blood sugar. Chinese patent CN2014102016199 also discloses a method for extracting and purifying components inhibiting the activity of alpha-glucosidase from chestnut shells, which can be used for treating diabetes and obesity.
Disclosure of Invention
The invention aims to provide a composition capable of improving blood sugar level and a preparation method thereof, and the composition is rich in nutrition, convenient to eat, and capable of adjusting the blood sugar level and improving immunity.
The technical scheme of the invention is as follows.
Use of a composition comprising chestnut shell extract for the preparation of a food or pharmaceutical product for improving blood glucose levels.
A composition for improving blood sugar level comprises chestnut peel extract 25-40 parts, folium Mori extract 10-20 parts, and oat beta-dextran 3-5 parts, wherein the chestnut peel extract is obtained by extracting shell and endothelium together, wherein the ratio of chestnut shell and endothelium is 8-12: 1-3.
The chestnut shell (chestnut shell) is a shell for wrapping chestnut meat, and the shell is not a shell containing burrs if the chestnut is purchased daily.
Further, the chestnut peel extract is extracted by one or more mixed solvents selected from ethanol, butanol and water.
Inhibition of alpha-glucosidase and alpha-amylase activity in the gut is considered to be an effective method for the control of diabetes, as described in the background above, and related studies have explored the inhibition of alpha-glucosidase and alpha-amylase activity by chestnut peel extracts. In the research, the single chestnut peel extract has limited improvement effect, and the effect of improving the blood sugar level can be promoted to a certain extent by using other extracts and the chestnut peel together.
The composition for improving the blood sugar level also comprises 40 parts of chestnut peel extract, 15 parts of mulberry leaf extract and 5 parts of oat beta-glucan.
Further, the composition may further comprise one or more of fructus Momordicae Charantiae powder, chromium-containing yeast powder (chromium-rich yeast), fructus Momordicae Charantiae extract, fructus Hordei Germinatus, Haematococcus pluvialis powder, herba Avenae Fatuae fiber, rhizoma Dioscoreae powder, flos Chrysanthemi powder, semen Fagopyri Esculenti powder, rhizoma Polygonati Odorati powder, radix Puerariae powder, and vitamin B2; the contents of the components are as follows: 5-10 parts of bitter gourd powder, 1-2 parts of chromium-containing yeast powder, 5-10 parts of bitter gourd extract, 10-20 parts of barley malt, 5-10 parts of haematococcus pluvialis powder, 3-5 parts of oat fiber, 5-10 parts of yam powder, 1-2 parts of chrysanthemum powder, 3-5 parts of buckwheat powder, 4-7 parts of polygonatum powder, 3-5 parts of radix puerariae powder and 20.1-1 parts of vitamin B.
Further, the components comprise 30 parts of chestnut peel extract, 15 parts of mulberry leaf extract, 15 parts of barley malt, 5 parts of bitter gourd powder, 1 part of chromium-containing yeast powder, 10 parts of bitter gourd extract, 3 parts of oat beta-glucan, 10 parts of haematococcus pluvialis powder, 3 parts of oat fiber, 5 parts of yam powder, 1 part of chrysanthemum powder, 4 parts of buckwheat powder, 5 parts of polygonatum powder, 5 parts of radix puerariae powder and 20.3 parts of vitamin B.
The composition can also comprise 40 parts of chestnut peel extract, 10 parts of mulberry leaf extract, 10 parts of barley malt, 5 parts of bitter gourd powder, 1 part of chromium-containing yeast powder, 10 parts of bitter gourd extract, 3 parts of oat beta-glucan, 5 parts of haematococcus pluvialis powder, 3 parts of oat fiber, 5 parts of yam powder, 1 part of chrysanthemum powder, 3 parts of buckwheat powder, 4 parts of polygonatum powder, 5 parts of radix puerariae powder and 20.5 parts of vitamin B.
Preferably, the preparation method of the chestnut peel extract comprises the following steps:
(1) pre-treating, washing chestnut shell and chestnut inner skin, oven drying, and pulverizing into 50-80 mesh powder;
(2) soaking the inner skin and shell of chestnut in 55-60% ethanol solution for 3-5 hr, transferring the inner skin and shell of chestnut to an extraction tank, adding ethanol with a material-liquid ratio of 1:18-24 and ethanol concentration of 45-55%, reflux extracting for 2-3 times, each for 1-3 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 0.5-4 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
As for the chestnut extract, the chestnut shell and chestnut inner skin extract have certain effect of improving blood sugar, and researches show that when the chestnut shell and the chestnut inner skin extract are extracted together, the components have mutual dissolution promoting effect, and the obtained extract has better effect than the effect of improving the blood sugar level when a single component is extracted.
The preparation method of the composition for improving the blood sugar level comprises the following steps:
(1) weighing the raw materials according to the weight percentage, and mixing the raw materials into a mixed material;
(2) grinding the mixture, and sieving with 80-100 mesh sieve;
(3) sterilizing, cooling to room temperature, and packaging.
Further, the sterilization treatment adopts a microwave drying treatment mode, and the treatment conditions are as follows: the microwave power is 20-50kW, and the frequency is 2450 MHz.
Further, the composition can be packaged to provide a pouch product for ease of consumption.
Further, the product prepared by the preparation method can be food, health-care food or medicine, and is used for intervening or improving the blood sugar level.
In the prior art research, the mechanism of reducing blood fat by single components or monomers extracted from medicinal and edible traditional Chinese medicines is advanced to the molecular and gene level. Different compositions interfere the blood sugar level through multiple ways, multiple links and multiple targets, and all components interact and influence each other, so that the full synergy of the formula is the key point of research. The composition can effectively improve the blood sugar level by selecting a plurality of nutritional factor combinations with the function of improving the blood sugar level, and has rich nutrition and convenient eating.
According to researches, although chestnut peel extract is utilized as a relevant document for improving blood sugar level, the chestnut peel and the inner skin are compositely extracted according to the ratio of 8-12:1-3, so that the extraction of effective components is more facilitated, in addition, the mutual promotion effect of mulberry leaf extract, oat beta glucan and the chestnut peel extract also brings great influence on the improvement of the blood sugar level, alpha-amylase hydrolyzes carbohydrate into disaccharide, the disaccharide is hydrolyzed into monosaccharide by the alpha-glucosidase, and the inhibition effect on the activity of the alpha-glucosidase and the alpha-amylase in intestinal tracts is considered to be an effective method for controlling diabetes. The compositions of the present invention, as a whole, are compatible with each other to synergistically promote, inter alia, unexpected technical effects in inhibiting the activities of α -glucosidase and α -amylase and regulating blood glucose levels.
Detailed Description
Example 1
(1) Weighing 40 parts of chestnut peel extract, 15 parts of mulberry leaf extract and 5 parts of oat beta-glucan, and mixing to obtain a mixed material;
(2) grinding the mixture, sieving with 80-100 mesh sieve, and performing microwave drying treatment for sterilization under the following conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz;
(3) sterilizing, cooling to room temperature, and packaging.
The preparation method of the chestnut peel extract comprises the following steps: (1) pre-treating, namely respectively cleaning, drying and crushing the chestnut shells and the chestnut endothelium, wherein the crushing mesh is 50-80 meshes, and the weight ratio of the chestnut shells to the chestnut endothelium is 9: 2;
(2) soaking the inner skin and shell of chestnut in 55-60% ethanol solution for 4 hr, transferring the inner skin and shell of chestnut to an extraction tank, adding ethanol at a ratio of material to liquid of 1:20, wherein the ethanol concentration is 45-55%, and extracting under reflux for 3 times, each time for 1.5 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 3 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
Example 2
(1) Weighing 40 parts of chestnut peel extract, 40 parts of mulberry leaf extract and 30 parts of oat beta-glucan, and mixing to obtain a mixed material;
(2) grinding the mixture, sieving with 80-100 mesh sieve, and performing microwave drying treatment for sterilization under the following conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz;
(3) sterilizing, cooling to room temperature, and packaging.
The preparation method of the chestnut peel extract comprises the following steps: (1) pre-treating, namely respectively cleaning, drying and crushing the chestnut shells and the chestnut endothelium, wherein the crushing mesh is 50-80 meshes, and the weight ratio of the chestnut shells to the chestnut endothelium is 1: 1;
(2) soaking the inner skin and shell of chestnut in 55-60% ethanol solution for 4 hr, transferring the inner skin and shell of chestnut to an extraction tank, adding ethanol at a ratio of material to liquid of 1:20, wherein the ethanol concentration is 45-55%, and extracting under reflux for 3 times, each time for 1.5 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 3 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
Example 3
A composition for improving blood glucose level comprises the following components: 40 parts of chestnut peel extract, 10 parts of mulberry leaf extract, 10 parts of barley malt, 5 parts of bitter gourd powder, 1 part of chromium-containing yeast powder, 10 parts of bitter gourd extract, 5 parts of oat beta-glucan, 5 parts of haematococcus pluvialis powder, 3 parts of oat fiber, 5 parts of Chinese yam powder, 1 part of chrysanthemum flower powder, 3 parts of buckwheat powder, 4 parts of polygonatum powder, 5 parts of radix puerariae powder and 20.5 parts of vitamin B.
The preparation method comprises the following steps: (1) weighing the raw materials according to the weight percentage, and mixing the raw materials into a mixed material; (2) grinding the mixture, and sieving with 80-100 mesh sieve; (3) performing sterilization treatment on the product, wherein the sterilization treatment adopts a microwave drying treatment mode, and the treatment conditions are as follows: the microwave power is 20-50kW, and the frequency is 2450 MHz; cooling to room temperature, and packaging.
The preparation method of the chestnut peel extract comprises the following steps: (1) pre-treating, namely respectively cleaning, drying and crushing the chestnut shells and the chestnut endothelium, wherein the crushing mesh is 50-80 meshes, and the weight ratio of the chestnut shells to the chestnut endothelium is 9: 2;
(2) soaking the inner skin and shell of chestnut in 55-60% ethanol solution for 4 hr, transferring the inner skin and shell of chestnut to an extraction tank, adding ethanol at a ratio of material to liquid of 1:20, wherein the ethanol concentration is 45-55%, and extracting under reflux for 3 times, each time for 1.5 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 3 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
Comparative example 1
(1) Weighing 60 parts of chestnut peel extract;
(2) grinding the chestnut peel extract, sieving with a 80-100 mesh sieve, and performing microwave drying treatment for sterilization under the following conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz;
(3) sterilizing, cooling to room temperature, and packaging.
The chestnut shell extract was prepared in the same manner as in example 1.
Comparative example 2-1
(1) Grinding 40 parts of chestnut peel extract, sieving with a 80-100 mesh sieve, and performing microwave drying treatment for sterilization under the following treatment conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz;
(2) sterilizing, cooling to room temperature, and packaging.
The preparation method of the chestnut peel extract comprises the following steps: (1) pretreating, cleaning, drying and crushing chestnut shells, wherein the crushing mesh number is 50-80 meshes;
(2) soaking pulverized chestnut shell in 55-60% ethanol solution for 4 hr, transferring the chestnut shell into an extraction tank, adding ethanol with a material-liquid ratio of 1:20, wherein the ethanol concentration is 45-55%, and reflux-extracting for 3 times, each for 1.5 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 3 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
Comparative examples 2 to 2
(1) Grinding 40 parts of chestnut peel extract, sieving with a 80-100 mesh sieve, and performing microwave drying treatment for sterilization under the following treatment conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz;
(2) sterilizing, cooling to room temperature, and packaging.
The preparation method of the chestnut shell extract is the same as that of the comparative example 2-1, the raw materials are different, and the chestnut shells are replaced by the chestnut inner shells with the same total weight fraction.
Effect of the experiment
The composition has alpha-glucosidase inhibiting effect.
And detecting the reaction of PNPG and alpha-glucosidase to generate yellow-green p-nitrophenol, and judging the inhibitory activity of the sample according to the absorbance of the solution.
The determination method is judged by using the common absorbance value in the prior art, and specifically comprises the following steps: 100. mu.L (100 mmol/L) of PNPG was added to 850. mu.L of phosphate buffer. Then adding the sample solution, wherein the mass concentration of the sample solution is 50 mug/mL. The control group is a reaction system without adding enzyme and sample solution to eliminate the influence of p-nitrophenol generated by PNPG oxidation on the determination result, the blank group is a system with enzyme but no sample solution, and the background control group is a system with inhibitor but no enzyme. Incubating at 37 deg.C for 10min, adding alpha-glucosidase 50 μ L, incubating for 50min, adding 1mL sodium carbonate to terminate reaction, and measuring absorbance at 405 nm; wherein the sample solutions were set as example 1, example 2, comparative example 1, comparative examples 2-1, 2-2.
Inhibition (100%) =100 x [ a-B- (C-D) ]/(a-B);
where A is the reading of the blank at A520, B is the reading of the control at A520, C is the reading of the sample solution at A520, and D is the reading of the background control at A520.
The results show that the inhibition rates are respectively: the inhibition ratio of example 1 was 95.2%, the inhibition ratio of example 2 was 90.4%, the inhibition ratio of comparative example 1 was 86.7%, and the inhibition ratios of comparative examples 2-1 and 2-2 were 75.7% and 79.8%.
Determination of blood glucose levels
The test method comprises the following steps: male mice were selected for SPF grade, free to ingest, drink, and after 1 week of adaptive feeding, prohibited for 24h, and mice were randomly divided into 6 groups: example 3 low dose group, example 3 medium dose group, example 3 high dose group, positive drug group, model control group, blank control group. The experimental group (except blank control group) is injected intraperitoneally with the modeling agent, after 5d, the patient is fasted for 4h, and the blood sugar is measured, wherein the blood sugar value is more than 10mmol/L, and the group is the diabetes model group.
A molding agent: streptozotocin (STZ), freshly prepared at a concentration of 13.0mg/ml with 0.1mol/L, pH =4.2 sodium citrate buffer.
And (3) testing a sample: prepared as in example 3, suspensions of 10mg/ml, 20mg/ml, 40mg/ml, respectively, were prepared in water.
Positive drug: acarbose tablets were ground to a powder and made up in water to a suspension with a concentration of 10 mg/ml.
The experimental method comprises the following steps: the oral gavage is carried out, a blank control group is a normal feeding mouse, molding treatment is not carried out, and a model group is gavage with normal saline with the same volume.
The experimental time was 30 days, and the dose was given daily at regular intervals. Blood glucose values were measured on days 0, 10, 20, and 30.
Percent blood glucose decrease = (blood glucose before experiment-blood glucose after experiment)/blood glucose before experiment x 100%.
Data analysis
The differences were analyzed using SPSS software.
Compared with the model group, the positive drug group has a significant blood sugar lowering effect, and the composition of the embodiment 3 of the invention has a blood sugar improving effect in all three dose groups, and the effect is weaker than that of the positive drug group.
| Group of | Blood sugar mmol/L (0 d) | Blood sugar mmol/L (10 d) | Blood sugar mmol/L (20 d) | Blood sugar value mmol/L (30 d) | Percentage of blood glucose decrease |
| Low dose group | 20.35±1.22 | 18.34±2.22 | 17.65±1.49 | 16.18±1.25 | 20.49% |
| Middle dose group | 20.14±1.32 | 18.01±2.31 | 16.14±1.56 | 14.01±1.68 | 30.43% |
| High dose group | 20.89±1.28 | 17.45±2.17 | 14.38±1.78 | 11.25±1.78 | 46.15% |
| Blank group | 4.58±0.42 | 4.55±0.74 | 4.54±0.23 | 4.53±0.15 | 1.09% |
| Model control group | 21.13±1.41 | 23.25±2.24 | 26.78±2.64 | 29.37±2.15 | -39.35% |
| Positive drug group | 20.94±1.29 | 15.78±2.14 | 12.46±2.31 | 8.79±1.57 | 58.23% |
It should be understood that the above-described embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.
Claims (4)
1. A composition capable of improving blood sugar level is characterized by comprising 25-40 parts of chestnut peel extract, 10-20 parts of mulberry leaf extract, 3-5 parts of oat beta-glucan, 5-10 parts of bitter gourd powder, 1-2 parts of chromium-containing yeast powder, 5-10 parts of bitter gourd extract, 10-20 parts of barley malt, 5-10 parts of haematococcus pluvialis powder, 3-5 parts of oat fiber, 5-10 parts of yam powder, 1-2 parts of chrysanthemum powder, 3-5 parts of buckwheat powder, 4-7 parts of polygonatum odoratum powder, 3-5 parts of radix puerariae powder and 20.1-1 parts of vitamin B, wherein the chestnut peel extract is obtained by extracting shells and endothelium together to obtain an extract, wherein the ratio of the chestnut shell to the endothelium is 9: 2;
the preparation method of the chestnut peel extract comprises the following steps: (1) pre-treating, washing chestnut shell and chestnut inner skin, oven drying, and pulverizing into 50-80 mesh powder;
(2) soaking the inner skin and shell of chestnut in 55-60% ethanol solution for 3-5 hr, transferring the inner skin and shell of chestnut to an extraction tank, adding ethanol with a material-liquid ratio of 1:18-24 and ethanol concentration of 45-55%, reflux extracting for 2-3 times, each for 1-3 hr;
(3) combining the extracts, and removing the residue by filtration; concentrating under reduced pressure at 40-50 deg.C for 0.5-4 hr to obtain concentrated extract;
(4) freeze drying the concentrated extract to obtain powdered chestnut peel extract.
2. A method for preparing the composition for improving blood glucose level according to claim 1, comprising the steps of:
(1) weighing the raw materials in parts by weight, and mixing to obtain a mixed material;
(2) grinding the mixture, and sieving with 80-100 mesh sieve;
(3) sterilizing, cooling to room temperature, and packaging.
3. The method according to claim 2, wherein the sterilization treatment is a microwave drying treatment under the following conditions: the microwave power is 20-50kW, and the frequency is 2450 MHz.
4. The method according to claim 2, wherein the product is processed into health food or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810373933.3A CN108523126B (en) | 2018-04-24 | 2018-04-24 | Composition for improving blood sugar level and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810373933.3A CN108523126B (en) | 2018-04-24 | 2018-04-24 | Composition for improving blood sugar level and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108523126A CN108523126A (en) | 2018-09-14 |
| CN108523126B true CN108523126B (en) | 2021-11-09 |
Family
ID=63478625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810373933.3A Active CN108523126B (en) | 2018-04-24 | 2018-04-24 | Composition for improving blood sugar level and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108523126B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111493244A (en) * | 2020-03-29 | 2020-08-07 | 湖南省拜尔艾克斯生物技术有限公司 | Edible plant blood sugar reducing beverage and preparation method thereof |
| CN114081172A (en) * | 2020-08-25 | 2022-02-25 | 上海屹泽生物科技有限公司 | Blood sugar and blood pressure controlling composition, blood sugar and blood pressure controlling tablet candy and preparation method thereof |
| CN112352805A (en) * | 2020-10-14 | 2021-02-12 | 杭州赛能医药科技有限公司 | High-protein high-dietary-fiber particle nutrition bar and manufacturing method thereof |
| CN112262989A (en) * | 2020-11-04 | 2021-01-26 | 光瀚健康咨询管理(上海)有限公司 | Protein sugar-control meal replacement powder and preparation method thereof |
| CN112471257B (en) * | 2020-11-23 | 2023-10-20 | 江西阳光乳业股份有限公司 | Yoghurt with blood glucose and blood lipid reducing functions |
| CN112401239A (en) * | 2020-12-07 | 2021-02-26 | 广州正广生物科技有限公司 | Composition for reducing blood sugar and preparation method and application thereof |
| CN112544766B (en) * | 2020-12-09 | 2024-03-15 | 杭州衡美食品科技有限公司 | Nut bar suitable for hyperglycemia population to eat and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006001872A (en) * | 2004-06-16 | 2006-01-05 | Kanebo Ltd | alpha-GLUCOSIDASE INHIBITOR AND FOOD USING THE SAME |
| CN1724660A (en) * | 2005-07-08 | 2006-01-25 | 山东绿润食品有限公司 | production method of extracting saccharic clastic enzyme in Chinese chestnut membrane |
| CN101018557A (en) * | 2004-09-13 | 2007-08-15 | 辻田隆广 | Carbohydrase inhibitors derived from chestnut and use thereof |
| CN101904492A (en) * | 2010-03-25 | 2010-12-08 | 马宏达 | Preparation method of functional food for regulating blood sugar to promote balance of internal organs |
| CN103535708A (en) * | 2011-07-19 | 2014-01-29 | 江西江中制药(集团)有限责任公司 | Technology for reducing in-vivo decomposition and absorption speeds of starch |
| CN103948654A (en) * | 2014-05-13 | 2014-07-30 | 北京林业大学 | Method of extracting, purifying and inhibiting alpha-glucosaccharase active ingredient from chestnut shell |
| CN104473152A (en) * | 2014-11-19 | 2015-04-01 | 石泽 | Biological medicated food equivalent to acarbose physical method for reducing postprandial blood sugar |
| CN105595308A (en) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | Chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function and preparation method thereof |
| CN105902583A (en) * | 2016-05-19 | 2016-08-31 | 郭传明 | Chestnut shell extract and preparation method and application thereof |
| CN106666380A (en) * | 2016-12-29 | 2017-05-17 | 广东省农业科学院蚕业与农产品加工研究所 | Preparation method and application of compound food base material enriched with blood glucose reducing factors |
| CN107095291A (en) * | 2017-05-03 | 2017-08-29 | 杨涵 | It is a kind of to activate the natural meals that islet cells promotes metabolism of blood glucose |
-
2018
- 2018-04-24 CN CN201810373933.3A patent/CN108523126B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006001872A (en) * | 2004-06-16 | 2006-01-05 | Kanebo Ltd | alpha-GLUCOSIDASE INHIBITOR AND FOOD USING THE SAME |
| CN101018557A (en) * | 2004-09-13 | 2007-08-15 | 辻田隆广 | Carbohydrase inhibitors derived from chestnut and use thereof |
| CN1724660A (en) * | 2005-07-08 | 2006-01-25 | 山东绿润食品有限公司 | production method of extracting saccharic clastic enzyme in Chinese chestnut membrane |
| CN101904492A (en) * | 2010-03-25 | 2010-12-08 | 马宏达 | Preparation method of functional food for regulating blood sugar to promote balance of internal organs |
| CN103535708A (en) * | 2011-07-19 | 2014-01-29 | 江西江中制药(集团)有限责任公司 | Technology for reducing in-vivo decomposition and absorption speeds of starch |
| CN103948654A (en) * | 2014-05-13 | 2014-07-30 | 北京林业大学 | Method of extracting, purifying and inhibiting alpha-glucosaccharase active ingredient from chestnut shell |
| CN104473152A (en) * | 2014-11-19 | 2015-04-01 | 石泽 | Biological medicated food equivalent to acarbose physical method for reducing postprandial blood sugar |
| CN105595308A (en) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | Chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function and preparation method thereof |
| CN105902583A (en) * | 2016-05-19 | 2016-08-31 | 郭传明 | Chestnut shell extract and preparation method and application thereof |
| CN106666380A (en) * | 2016-12-29 | 2017-05-17 | 广东省农业科学院蚕业与农产品加工研究所 | Preparation method and application of compound food base material enriched with blood glucose reducing factors |
| CN107095291A (en) * | 2017-05-03 | 2017-08-29 | 杨涵 | It is a kind of to activate the natural meals that islet cells promotes metabolism of blood glucose |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108523126A (en) | 2018-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108523126B (en) | Composition for improving blood sugar level and preparation method thereof | |
| CN101116487A (en) | Instant nutritive gruel having a function of stabilizing body blood sugar after meal and method for preparing the same | |
| US20100048505A1 (en) | Composition Having Effect of Treating, Preventing, or Improving Diabetes or Diabetic Complication and Drink Comprising the Same | |
| CN107981324A (en) | Turmeric fermented food and preparation method thereof | |
| CN103156896B (en) | Preparation method for novel red ginseng using reduced-pressure drying after high temperature high pressure process | |
| JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
| CN105558737A (en) | Sugar-free edible fungus solid drink and preparation method thereof | |
| KR101113931B1 (en) | A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same | |
| CN107530315A (en) | Energetic supersession activator in muscle cell | |
| US20020018818A1 (en) | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage | |
| CN103977409A (en) | Dietary supplement composition and blood sugar regulating method thereof | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN109069562A (en) | Polysaccharide digests inhibitor | |
| KR101391441B1 (en) | Composition for improving constipation or intestinal function comprising fermented rice extracts | |
| US20230241147A1 (en) | Method for improving preparation of fermented black ginseng containing high content of functional ingredients based on safety by applying led | |
| KR20170077980A (en) | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
| CN105176773A (en) | Pumpkin wine capable of adjusting blood glucose and making method thereof | |
| CN102250724B (en) | Cordyceps and ginkgo yellow wine as well as preparation method and application thereof | |
| JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
| JP2002053484A (en) | Lipase inhibitor, and food and drink containing the same | |
| KR20190078182A (en) | Composition for Removing Hangover Using an Extract of Enteromorpha prolifera, Sprout Ginseng etc. | |
| JP2006256969A (en) | Blood flow ameliorant | |
| CN112450435A (en) | Health food for reducing blood sugar and blood fat and preparation method thereof | |
| KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
| JP2006265142A (en) | Body fat accumulation inhibiting or decreasing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |